Ruplizumab

Ruplizumab?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD154
Clinical data
Trade names Antova
Identifiers
220651-94-5 
None
Chemical data
  (what is this?)  (verify)

Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms,[1] while another study only found thrombocytopenia.[2]

References

  1. ↑ Liossis, SN; Sfikakis, PP (2004). "Costimulation blockade in the treatment of rheumatic diseases". BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 18 (2): 95–102. doi:10.2165/00063030-200418020-00003. PMID 15046525.
  2. ↑ Nakamura, M; Tanaka, Y; Satoh, T; Kawai, M; Hirakata, M; Kaburaki, J; Kawakami, Y; Ikeda, Y; Kuwana, M (2006). "Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism". Rheumatology (Oxford, England) 45 (2): 150–6. doi:10.1093/rheumatology/kei118. PMID 16188945.